EVP-ABD Enhanced MRI for Evaluation Liver Disease

EVP-ABD 增强 MRI 评估肝病

• 批准号: 7157055
• 负责人: Peter R Seoane
• 金额: $ 15.32万
• 依托单位: EAGLE VISION PHARMACEUTICAL CORPORATION
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-15 至 2007-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7157055
• 关键词: bioimaging /biomedical imaging; contrast media; diagnosis design /evaluation; diagnosis quality /standard; disease /disorder classification; disease /disorder model; hepatitis; histopathology; image enhancement; laboratory rat; liver disorder diagnosis; magnetic resonance imaging; noninvasive diagnosis; pathologic process; pharmacokinetics; statistics /biometry; technology /technique development

DESCRIPTION (provided by applicant): Project Summary/Abstract: Hepatitis deriving from viral infection and chemical, drug or alcohol toxicity is placing a growing burden on the health care system. While initial diagnosis of hepatitis may rely on medical history, Liver Function Tests (LFT), Polymerase Chain Reaction (PCR) results, etc.; confirmation, characterization (grading and staging) and follow-up of hepatitis relies on liver biopsy as the gold standard despite significant morbidity and a small but definite risk of mortality associated with the procedure. A non-invasive test that would provide a reliable measure of the nature and magnitude of diffuse liver disease, correlating to histology and thereby reducing the dependence on periodic biopsies would meet a major unmet need. Eagle Vision Pharmaceutical Corp (EAGLE) is developing EVP-ABD, an intracellular manganese based Magnetic Resonance Imaging (MRI) contrast agent, with unique magnetic and kinetic properties. The potential for correlation between the energy dependent intracellular uptake of EVP-ABD (assessed noninvasively by MRI imaging) and liver function (assessed by histology) will be evaluated in this study. Project Narrative: The long term goal of the research is to register and commercialize EVP-ABD in the US and elsewhere as a contrast agent for diagnosis, characterization and assessing effectiveness of treatment of diffuse liver disease. If successful, EVP-ABD should reduce the dependence on serial liver biopsies by providing a noninvasive assessment of diffuse liver disease, and thus reduce the morbidity associated with the procedure.

项目摘要/摘要：由病毒感染和化学、药物或酒精毒性引起的肝炎正在给卫生保健系统带来越来越大的负担。虽然肝炎的初步诊断可能依赖于病史、肝功能检查（LFT）、聚合酶链反应（PCR）结果等；肝炎的确认、特征（分级和分期）和随访依赖于肝活检作为金标准，尽管肝活检有显著的发病率和小但明确的死亡风险。一种非侵入性检查能够可靠地衡量弥漫性肝病的性质和程度，并与组织学相关联，从而减少对定期活检的依赖，这将满足一个主要的未满足需求。Eagle Vision制药公司（Eagle）正在开发EVP-ABD，一种细胞内锰基磁共振成像（MRI）造影剂，具有独特的磁性和动力学特性。EVP-ABD的能量依赖性细胞内摄取（通过无创MRI成像评估）与肝功能（通过组织学评估）之间的潜在相关性将在本研究中进行评估。项目描述：该研究的长期目标是在美国和其他地方注册并商业化EVP-ABD，作为弥漫性肝病的诊断、表征和治疗效果评估的造影剂。如果成功，EVP-ABD应该通过提供弥漫性肝病的无创评估来减少对系列肝活检的依赖，从而减少与该手术相关的发病率。

项目成果

EVP-ABD-enhanced MRI to evaluate diffuse liver disease in a rat model.

EVP-ABD 增强 MRI 评估大鼠模型中的弥漫性肝病。

• DOI: 10.1002/jmri.21385
• 发表时间: 2008
• 期刊: Journal of magnetic resonance imaging : JMRI
• 作者: Zuo,ChunS;Seoane,PeterR;Thomsen,Morgane;Gillis,Tim;Meloni,Edward;Harnish,PhillipP;Renshaw,PerryF
• 通讯作者: Renshaw,PerryF